U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H25N5O4
Molecular Weight 459.4971
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of APIXABAN

SMILES

COC1=CC=C(C=C1)N2N=C(C(N)=O)C3=C2C(=O)N(CC3)C4=CC=C(C=C4)N5CCCCC5=O

InChI

InChIKey=QNZCBYKSOIHPEH-UHFFFAOYSA-N
InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)

HIDE SMILES / InChI

Description

Apixaban is an orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the conversion of prothrombin to thrombin and preventing formation of cross-linked fibrin clots. Apixaban has been available in Europe since May 2012. An FDA decision on apixaban which was expected on June 28, 2012 was initially delayed before final approval on December 28, 2012. On August 21, 2014, Pfizer announced that apixaban was now FDA approved for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It is being developed in a joint venture by Pfizer and Bristol-Myers Squibb. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.22 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
ELIQUIS
Secondary
ELIQUIS

Cmax

ValueDoseCo-administeredAnalytePopulation
207 ng/mL
10 mg single, oral
APIXABAN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
2024 ng × h/mL
10 mg single, oral
APIXABAN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
12 h
10 mg single, oral
APIXABAN plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended dose is 5 mg orally twice daily. In patients with at least 2 of the following characteristics: age 80 years, body weight 60 kg, or serum creatinine 1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown